洞察
Insights From Our Experts
Articles
Insights From Trade & Channel Strategies Conference 2020
Now more than ever, pharma manufacturers need to break the cycle of supply chain complexity to better connect patients to therapy. On Tuesday, December 1, EVERSANA’s Scot Buchanan moderated the panel “Emerging and Future Trends in Channel…
DSCSA Guidelines – Best Practices for Compliance and Supply Chain Integration
On November 27, 2023, all drug manufacturers must participate in an electronic package-level traceability system, commonly known as the “interoperability” requirement. EVERSANA is equipped to help manufacturers navigate these new guidelines and apply best practices. Let’s…
A New Pharmaceutical Strategy for Europe
In late November, the European Commission announced the adoption of a new healthcare plan – the Pharmaceutical Strategy for Europe. This plan aims to strengthen the European Health Union while ensuring affordable patient access across the…
Ensuring Speed, Scale and Certainty in Supply Chain
Every twist and turn in the bench-to-bedside commercialization journey introduces increasing regulatory complexity, product-specific special handling requirements, and evolving industry guidelines. With more than 300 client case studies to draw from, we’ve found three opportunities (or…
Breaking the Cycle of Supply Chain Complexity
As the industry evolves with new regulatory guidelines and product-specific handling requirements, manufacturers now require an agile business model with integrated distribution services. In his new point of view article, Danny Williams, explains how manufacturers can…
Looking To Launch Or Commercialise In The US?
Launching a product is a serious undertaking, requiring a seamless approach to building a commercialisation strategy that includes all the variables needed to maximise the investment across the product’s lifecycle. Nowhere is this more true than…
The New Gold Standard of Drug Commercialization
Manufacturers spend >$125MM over three years leading up to launch, yet 66% of drugs don’t meet launch expectations. An unpredictable landscape, coupled with inevitable industry pressures, is forcing manufacturers to seek a more complete commercialization approach…
Trends Disrupting Life Sciences in 2020
From the commercialization of digital medicines to the evolution of value-driven healthcare – our thought leaders deliver insight on the trends impacting the life science industry that will continue to shape our thinking well in 2020…
Ask the Expert – Specialty Pharmacies and Specialty Distributors
According to a recent study from Health Strategies Insights by EVERSANA, 35%-45% of pipeline drugs are infusions and injectables that require nursing services, patient education, cold chain, new reimbursement measures and sites of care. Where is…
Integrated Delivery Networks: Learning to Engage With a New Customer With Very Different Needs
As the healthcare provider landscape rapidly evolves to deliver on the promises of value-based care and efficiencies of scale, integrated delivery networks (IDNs) have emerged as a dominant force in the US market. Meanwhile, biopharmaceutical manufacturers…